At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An International, Double-blind, Randomised, Placebo-Controlled Phase III Study to Evaluate the Effect of Dapagliflozin on Reducing CV Death or Worsening Heart Failure in Patients With Heart Failure With Preserved Ejection Fraction (HFpEF)
In Brief
A Phase 3 clinical trial evaluating Dapagliflozin and Placebo for Heart Failure With Preserved Ejection Fraction. Completed, enrolled 6,263 participants across 348 sites in 20 countries.
Detailed Summary
This is an international, multicentre, parallel-group, event-driven, randomised, double-blind, placebo-controlled study in HFpEF patients, evaluating the effect of dapagliflozin 10 mg versus placebo, given once daily in addition to background regional standard of care therapy, including treatments to control co-morbidities, in reducing the composite of CV death or heart failure events.
Study Details
Timeline
Interventions
10 mg tablets given once daily, per oral use.
Placebo matching dapagliflozin 10 mg